Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/011902LACTOBACILLUS PARACASEI AND APPLICATION THEREOF IN PREPARING MEDICINE FOR TREATING ULCERATIVE COLITIS
WO 20.01.2022
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
Appl.No PCT/CN2020/128122 Applicant FOSHAN LANGSEE BIOTECHNOLOGY CO., LTD. Inventor ZENG, Jincheng
A strain of Lactobacillus paracasei L.p R3-10 and an application thereof in preparing a medicine for treating ulcerative colitis, which belong to the field of biotechnology. Said bacterium is a strain of Lactobacillus which is obtained after L.p R3 acclimates to starvation for 10 generations and in which low nutrient gradient tolerance is induced. The deposit number of the bacterium is CGMCC No.19520. L.p R3-10 can be prepared to form a medicine for treating ulcerative colitis.
2.WO/2022/012682CD22 BINDING MOLECULES AND USES THEREOF
WO 20.01.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/106891 Applicant NANJING LEGEND BIOTECH CO., LTD. Inventor FAN, Xiaohu
The present disclosure provides single domain antibodies that bind to CD22, and chimeric antigen receptors comprising same. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
3.WO/2022/011436METHODS OF TREATING CORONAVIRUS INFECTION WITH BOVINE-HYPERIMMUNE COLOSTRUM
WO 20.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/AU2021/050772 Applicant IMMURON LIMITED Inventor KANELLOS, Jerry
A method of treating and/or preventing human coronavirus infection in a subject comprising administering an effective amount of a composition comprising bovine-hyperimmune colostrum prepared using a vaccine comprising enterotoxigenic E. coli (ETEC) LPS.
4.WO/2022/012531METHOD FOR PREPARING MODIFIED IMMUNE CELL
WO 20.01.2022
Int.Class C12N 15/90
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
90Stable introduction of foreign DNA into chromosome
Appl.No PCT/CN2021/106007 Applicant CURE GENETICS CO., LTD Inventor JIA, Luying
A method for preparing a modified immune cell. The modification comprises the following steps: a) reducing the expression and/or activity of a Fas protein in the immune cell, and b) increasing the expression and/or activity of a FasL protein in the immune cell. Thus, compared to an immune cell which is not subjected to the modification, the expression and/or activity of the Fas protein in the modified immune cell are reduced or eliminated, and the expression and/or activity of the FasL protein in the modified immune cell are increased.
5.WO/2022/012591ENGINEERED IMMUNE CELL FOR ALLOTRANSPLANTATION
WO 20.01.2022
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Appl.No PCT/CN2021/106259 Applicant NANJING BIOHENG BIOTECH CO., LTD Inventor ZHOU, Yali
Provided is an engineered immune cell. The expressions of at least one MHC related gene and at least one NK activating receptor binding molecule are suppressed or silenced, so as to suppress the killing of the engineered immune cell by NK cells. Also provided are a pharmaceutical composition containing the engineered immune cell and a use of the engineered immune cell in preparation of drugs for treatment of cancer, infection, or autoimmune diseases.
6.WO/2022/013236METHOD FOR PRODUCING A MAMMALIAN BRAIN PROTEIN HYDROLYSATE
WO 20.01.2022
Int.Class C07K 1/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
14Extraction; Separation; Purification
Appl.No PCT/EP2021/069495 Applicant EVER NEURO PHARMA GMBH Inventor HASELGRÜBLER, Thomas
Disclosed is a method for producing a mammalian brain protein hydrolysate, comprising the following steps: - providing a mammalian brain protein hydrolysate, - adding Zn ions to the mammalian brain protein hydrolysate to form a complex comprising the Zn ions and the mammalian brain protein hydrolysate, - obtaining the complex comprising the Zn ions and the mammalian brain protein hydrolysate in a mammalian brain protein hydrolysate composition.
7.WO/2022/016041CHONDROCYTE CELL SHEETS AND METHODS FOR THEIR PRODUCTION AND USE
WO 20.01.2022
Int.Class A61K 35/32
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
Appl.No PCT/US2021/041942 Applicant UNIVERSITY OF UTAH RESEARCH FOUNDATION Inventor EGAMI, Mime
The disclosure provides a chondrocyte cell sheet comprising one or more layers of confluent cells comprising chondrocytes and chondroprogenitor cells. Methods of generating cartilage tissue in a subject are also provided. The disclosure also provides a method for producing chondrocyte cell sheets comprising culturing chondrocytes and chondroprogenitor cells in culture solution on a temperature-responsive polymer which has been coated onto a substrate surface of a cell culture support, wherein the temperature-responsive polymer has a lower critical solution temperature in water of 0-80°C; adjusting the temperature of the culture solution to below the lower critical solution temperature, whereby the substrate surface is made hydrophilic and adhesion of the cell sheet to the surface is weakened; and detaching the cell sheet from the culture support.
8.WO/2022/012567NEW USE OF REGEND001 CELL AUTOLOGOUS REINFUSION PREPARATION IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
WO 20.01.2022
Int.Class C12N 5/071
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
Appl.No PCT/CN2021/106176 Applicant REGEND THERAPEUTICS CO., LTD. Inventor ZHANG, Ting
The present invention provides a REGEND001 cell autologous reinfusion preparation, and an application thereof in preparing a product for improving the pulmonary function of a patient suffering from idiopathic pulmonary fibrosis. The preparation is prepared by collection, in vitro isolation and culture and expansion of the patient's autologous bronchial basal cells.
9.WO/2022/013407THERAPEUTIC MICROBES
WO 20.01.2022
Int.Class A61K 35/66
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
Appl.No PCT/EP2021/069895 Applicant DANMARKS TEKNISKE UNIVERSITET Inventor BONGERS, Mareike
The invention relates to microbial cells and microbial cells for use as a medicament, the cells expressing a recombinant nucleic acid encoding a eukaryotic tyrosine hydroxylase. The cells produce L-DOPA and dopamine.
10.WO/2022/013872PSEUDOTYPED VIRUSES CONFIGURED TO EXPRESS CAR IN T-CELLS
WO 20.01.2022
Int.Class C12N 7/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
04Inactivation or attenuation; Producing viral sub-units
Appl.No PCT/IL2021/050863 Applicant ICHILOV TECH LTD. Inventor NAJJAR, Amer M
The present invention discloses a fusion protein comprising a vesicular stomatitis virus envelope glycoprotein (VSVG) extracellular domain or a fragment or an analog thereof linked to a polypeptide comprising an antigen binding domain specific to cluster of differentiation 3 (CD3). The application also discloses pseudo typed viruses comprising the fusion protein and pseudotyped viruses encoding for a chimeric antigen receptor (CAR) or T-cell receptor pseudotyped in which the receptor is expressed under a CD3 promoter. Pseudotyped viruses combining these properties are encompassed as well. The application further discloses use of these pseudotyped viruses and method of producing these pseudotyped viruses.